(Q36839672)

16 August 2017

1 reference

title

HER2-positive breast cancer: current and future treatment strategies (English)

1 reference

Her2-receptor positive breast cancer

16 August 2017

0 references

author name string

Ryan H Engel

series ordinal

1

1 reference

PubMed ID

17547474

16 August 2017

Virginia G Kaklamani

series ordinal

2

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

67

1 reference

16 August 2017

9

1 reference

16 August 2017

1329-1341

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767090-00006

16 August 2017

0 references

cites work

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767090-00006

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

12 December 2020

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

12 December 2020

Antibody therapy for breast cancer

1 reference

12 December 2020

Docetaxel/trastuzumab combination therapy for the treatment of breast cancer

1 reference

12 December 2020

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

1 reference

12 December 2020

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

12 December 2020

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer

1 reference

12 December 2020

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

12 December 2020

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

12 December 2020

Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables.

1 reference

12 December 2020

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

1 reference

12 December 2020

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

12 December 2020

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

1 reference

12 December 2020

A Phase II Trial with Trastuzumab and Pertuzumab in Patients with HER2-Overexpressed Locally Advanced and Metastatic Breast Cancer

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Cancer statistics, 2006

1 reference

12 December 2020

HER-2/neu signal transduction in human breast and ovarian cancer

1 reference

12 December 2020

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial

1 reference

12 December 2020

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.

1 reference

12 December 2020

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

12 December 2020

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

1 reference

12 December 2020

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

12 December 2020

Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells

1 reference

12 December 2020

Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

1 reference

12 December 2020

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

12 December 2020

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

12 December 2020

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

12 December 2020

Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications

1 reference

12 December 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

12 December 2020

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

1 reference

12 December 2020

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

HER-2/neu as a predictive marker of response to breast cancer therapy

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

12 December 2020

Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22

1 reference

12 December 2020

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

1 reference

12 December 2020

HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis

1 reference

12 December 2020

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

12 December 2020

Trastuzumab and chemotherapeutics: drug interactions and synergies.

1 reference

12 December 2020

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

12 December 2020

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

12 December 2020

Biomolecular markers of breast cancer

1 reference

12 December 2020

Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Herceptin: mechanisms of action and resistance

1 reference

12 December 2020

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

1 reference

12 December 2020

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

12 December 2020

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020

10.2165/00003495-200767090-00006

Identifiers

DOI

1 reference

PubMed ID

17547474

Dimensions Publication ID

16 August 2017

0 references

1 reference

PubMed ID

17547474